Join Us at TIDES USA 2026 in Hynes Convention Center! Mark your calendars! TIDES USA 2026—the premier event for oligonucleotide and peptide therapeutics—is coming to Boston, MA, on May 11-14, 2026. Visit Sinopeg at Booth #1010 to explore cutting-edge solutions in: Custom PEG Derivatives (mPEG, heterobifunctional PEGs, branched PEGs) Lipid Nanoparticles (LNPs) & Lipidoids for nucleic acid delivery Innovative Linker Technologies & ADC Payloads Why Stop By? Discuss your formulation challenges with our PEGylation experts Discover high-purity excipients for mRNA, siRNA, and peptide therapies Learn how our GMP-grade materials accelerate preclinical-to-commercial transitions Spotlight Case Study: Ask us about our role in developing temperature-stable LNP formulations for a global mRNA vaccine partner! Schedule a 1:1 Meeting: Avoid the crowds—reserve your private session today: sales@sinopeg.com Can't attend? Explore our solutions online: http://www.sinopeg.com Let's shape the future of oligonucleotide and peptide therapeutics together! See you at #1010. #TIDES2026 DrugDiscovery #LNPs #mRNA #PeptideTherapeutics #BiotechInnovation

Spring brings another good news! Following the European patent allowance for cationic lipids in February 2026, our patent portfolio has achieved another milestone. In April 2026, several cationic lipid products independently developed by Sinopeg—including DHA-1, SNP24-1, SNP25-1, and SNP26-1—successfully received U.S. patent allowance, protected in the form of a Markush formula. With this, the DHA-1 series cationic lipids have now secured patent coverage in the three core markets of China, Europe, and the United States, establishing a global intellectual property moat for this key excipient of LNP delivery systems. Patent Title: Cationic Lipid, Liposome Containing Cationic Lipid, and Nucleic-Acid Pharmaceutical Composition Containing Liposome and Formulation and Application Thereof Patent Application No.: 18/269,728 Applicant: Xiamen Sinopeg Biotech Co., Ltd. Source: Notice of Allowance from the USPTO (screenshot) Patent Breakthrough: Comprehensive Coverage from China to Europe and the U.S. DHA-1, SNP24-1, SNP25-1, SNP26-1, and others are cationic lipids independently developed by Sinopeg. They feature high biocompatibility and high transfection efficiency, effectively bypassing existing patent restrictions and providing a reliable, localized alternative for the LNP delivery field. In terms of IP strategy, the patent journey for the DHA-1 series has been solid and methodical: September 2022: Granted Chinese patent (priority application). October 2023: Granted patent for PCT national phase entry in China. February 2026: Granted European patent, achieving full coverage in China and Europe. April 2026: Granted U.S. patent, protected in Markush formula form. Thus, the DHA-1 series cationic lipids now hold patent protection in all three major markets—China, Europe, and the U.S.—providing a strong legal foundation for compliant commercialization and global business expansion. Beyond patent coverage, DHA-1 also leads in regulatory compliance: it has successfully completed CDE pharmaceutical excipient filing in China (Filing No. F20230000445) and has submitted a U.S. FDA DMF (Filing No. 039452). Customers can directly reference Sinopeg's filed dossiers in both China and the U.S., significantly reducing submission preparation time and accelerating project progress. Markush Formula Allowance: Broader Protection, Stronger Barrier What is a Markush formula allowance, and how is it different from a standard compound patent? Simply put, the Markush formula is one of the most valuable forms of patent protection in the pharmaceutical compound field. It uses a "generic formula" approach, covering a class of compounds that share a common structure and similar properties, rather than protecting only a single structure. For this series of cationic lipids, this means: Broader protection – The patent covers not only the dozens of specific structures exemplified (including DHA-1, SNP24-1, SNP25-1, SNP26-1) but also other cationic lipid structures sharing the same core ...

As we prepare to welcome a season of strength, speed, and success, our team will be taking a short break to celebrate the Chinese New Year with our loved ones. Holiday Notice: We will be closed from February 15 to February 23. Normal business operations will resume on February 24. During this period, if you have any urgent inquiries or project needs, please feel free to: Leave us a message via our website: www.sinopeg.com Or email us at: sales@sinopeg.com We’ll get back to you promptly upon our return. Wishing you and your family a joyful, prosperous, and horse-powered New Year! #ChineseNewYear #YearOfTheHorse #SpringFestival #HolidayNotice #GlobalBusiness #Sinopeg #ClientCare #NewYear2026

Within the intricate system of Radiopharmaceutical Drug Conjugates (RDCs), there exists a component that, while seemingly auxiliary, is critically vital, directly impacting the drug's stability and targeting efficiency. This component is the monodisperse polyethylene glycol (PEG) derivative. Serving as the crucial linker in RDC drugs, it is quietly propelling tumor precision therapy into a new, more controllable and efficient phase. What are RDC Drugs? Structurally, Radiopharmaceutical Drug Conjugates (RDCs) primarily consist of a targeting ligand (Ligand, such as antibodies, peptides, or small molecules), a linker, a chelator, and a radioisotope. Their main mechanism involves using the targeting ligand to deliver the radioisotope to a specific target, leveraging the radiation effects of the radioisotope to achieve precise killing of tumor cells or imaging for medical diagnosis and treatment. (Image Source: WuXi AppTec Marketing Department WeChat Official Account) Globally, the R&D progress of RDC drugs is remarkable. Currently, over 10 RDC drugs have been approved for marketing, with several therapeutic radiopharmaceuticals achieving significant success in areas like neuroendocrine tumors and prostate cancer. These successes mark the formal entry of tumor treatment into a new era of precise targeted therapy. Compared to traditional chemotherapy, RDC drugs can act more precisely on tumor cells, improving treatment efficacy while reducing toxic side effects. Chinese pharmaceutical companies are also accelerating their deployment in this cutting-edge field. According to statistics from the MoShang Medical Database, as of now, over 120 domestic companies and institutions are involved in RDC R&D, demonstrating China's strong momentum in the field of nuclear medicine innovation. As an emerging force in tumor therapy, targeted radiopharmaceuticals stand at the forefront of the era's development, with their immense potential drawing significant attention. They are expected to become the next major breakthrough point in tumor treatment. The Wave of PEG-Modified Radiopharmaceutical R&D To date, numerous studies on PEG-modified peptide radiopharmaceuticals have been reported, and several radiopharmaceuticals in Phase II/III clinical trials have successfully employed PEG modification strategies. In the current wave of RDC R&D, high-quality, stably supplied key excipients are the cornerstone ensuring smooth R&D progress. As a dedicated player in the field of PEG derivatives, Sinopeg relies on its advanced synthesis and purification technology platform to provide a series of monodisperse PEG derivatives with well-defined structures, high purity, and functionalized termini, offering solid support for RDC drug R&D. As RDC drug R&D deepens, the demand for high-quality PEG derivatives will continue to grow. Professional and reliable suppliers will become an important force driving innovation in this field! Sinopeg boasts an extensive i...

Radioconjugate drugs—combining radionuclides with targeting ligands such as antibodies, peptides, or small molecules via chelators and linkers—represent a cutting-edge approach in precision medicine. By delivering radionuclides directly to disease sites, they enable targeted tumor ablation or highly accurate diagnostic imaging, revolutionizing both therapy and diagnostics. To enhance the stability, solubility, and pharmacokinetics of your radioconjugates, Sinopeg offers high-purity, monodisperse polyethylene glycol (PEG) derivatives. These well-defined PEG linkers ensure improved conjugation efficiency, reduced immunogenicity, and optimized in vivo performance—key factors for developing safe and effective radiopharmaceuticals. Whether you are designing novel radioligands or optimizing existing constructs, Sinopeg’s tailored PEG solutions can accelerate your R&D and help bring more precise, impactful treatments to patients. Reach out to explore how we can support your next-generation radioconjugate projects! Various Kingds And Grades Of Such Monodispersed Are Readily Avaliable| SINOPEG

Recently, SINOPEG's self-developed products, mPEG-DTA-1 and HO-PEG-DTA-5, have been formally granted European patents! This marks the recognition of domestically produced high-end LNP excipients by the international regulatory system, laying a solid foundation for China's innovative drugs to enter the global market! As core components of the LNP delivery system, the structure of PEG lipids decisively influences the safety, stability, and immunogenicity of the formulation. SINOPEG has always been committed to the research and development of new technologies and products, and has already secured a significant position in the field of domestic PEG lipid R&D. The newly authorized mPEG-DTA-1 and HO-PEG-DTA-5 are important achievements of the company's continuous innovation in the PEG lipid field. Innovation Breakthrough: mPEG-DTA-1 and HO-PEG-DTA-5 Granted European Patents HO-PEG-DTA-5 is a PEG lipid containing a hydroxyl terminal, which, together with its structural counterpart mPEG-DTA-1, forms the core layout of SINOPEG's product series in this category. To date, these two products have completed their global intellectual property layout: they obtained Chinese patent authorization back in 2023 (Patent No.: ZL202280003648.7) and recently received European patent authorization. (Screenshot source: European Patent Office, Link: https://register.epo.org/application?number=EP22784092&tab=main) Meanwhile, the independently developed mPEG-DTA-1 has already completed its filing with the CDE (Filing No.: F20230000444) and DMF submission (Filing No.: 039451). Even more encouragingly, HO-PEG-DTA-5 will soon complete dual submissions in China and the US, providing strong excipient support and registration convenience for Chinese innovative pharmaceutical companies aiming for the international mainstream pharmaceutical market! Note: For more product filing information, please feel free to contact us. LNP Technology: A Revolutionary Nano-Delivery Platform Lipid Nanoparticles (LNP), as one of the most successful nano-delivery carriers, have demonstrated exceptional capabilities in delivering cytotoxic chemotherapeutic drugs, antibiotics, and nucleic acid therapeutics. In recent years, with the rapid development of mRNA vaccines and drugs, the importance of LNP technology has become increasingly prominent, making it a focal point in the global pharmaceutical field. The granting of European patents for SINOPEG's products not only reflects the international intellectual property system's recognition of China's innovative achievements but also signifies that Chinese companies are steadily moving towards the center stage in the field of high-end pharmaceutical raw materials, potentially injecting new vitality into the global development of LNP technology. Product Portfolio: Extensive Layout Meets Diverse Needs Leveraging profound technical expertise, SINOPEG has developed a variety of novel PEG-lipid structures, providing more high-quality options for glo...

This golden autumn, SINOPEG ventured to Europe with its innovative products and solutions, making consecutive appearances at two premier international industry exhibitions within two months, engaging in deep exchanges with global pharmaceutical elites. CPHI Frankfurt 2025 (Frankfurt, Germany, Oct 28-30) As the world's largest and most influential professional event for the pharmaceutical industry, CPHI Frankfurt brought together industry elites from across the globe. In this grand gathering, SINOPEG attracted numerous visitors with its professional technical sharing. During the exhibition, we prominently showcased our latest achievements in areas such as in vivo CAR-T delivery, Antibody-Drug Conjugate (ADC) linkers, and block copolymers. We held in-depth discussions with multiple potential clients and partners from Europe, North America, and Asia! Many international clients praised our continuously improving R&D capabilities and product quality control system. TIDES Europe 2025 (Basel, Switzerland, Nov 11-13) Following closely, we moved to Switzerland to participate in TIDES Europe, an exhibition focused on oligonucleotides, peptides, mRNA therapies, and related fields. As one of the fastest-growing segments in biopharmaceuticals, TIDES provided us with a valuable platform for direct dialogue with global top experts. Here, we shared SINOPEG's technical expertise and project experience in fatty acid-modified side chains, LNP delivery material production, and related CMC services, attracting numerous biotechnology companies seeking reliable CDMO partners in this field. Through exchanges with industry benchmark companies, we further clarified our future technological development direction and innovation priorities. The successful participation in these two consecutive exhibitions allowed us to clearly grasp the development pulse of the global pharmaceutical industry chain. We deeply felt that CDMO enterprises from China are increasingly winning the trust of the global market, thanks to their continuously enhancing technical capabilities, flexible service models, and reliable quality systems. Two expeditions, two stages of growth. We brought back customer recognition, partner trust, and market insights – all of which will be invaluable assets for SINOPEG's future development! SINOPEG's journey on the international stage has just begun. We will continue to deepen our core technologies and expand our global footprint. Next year, we will appear on broader international stages, bringing more innovative solutions 'Made in China' to the global pharmaceutical industry. Stay tuned!